KIYATEC is ushering in a new world of cancer diagnostics that use living cells grown and tested in a more relevant 3D environment.
Clinical Cancer Diagnostics
KIYATEC is driving the future of clinical cancer diagnostics to provide more accurate prediction of patient-specific response to cancer treatments. Placing the patient's own living cancer cells into a more biologically relevant 3D culture environment, KIYATEC cell-based assays can better assist oncologists with improved response data and faster turnaround!
KIYATEC’s 3D cell-based models provide physiologically-relevant, efficient and cost-effective platforms for testing both small molecule and biologic drugs in an in vivo-like environment to better understand drug efficacy, response or resistance. Opportunities also exist for co-clinical trial partnering to apply ex vivo patient selection based on our Drug Response Profiling (DRP) approach. Read More
AACR 2015: Three KIYATEC Abstracts Accepted for Poster Presentations Read More
National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics Read More